Phase 1 dose-escalation trial of 611 in healthy volunteers
Latest Information Update: 28 Jul 2022
At a glance
- Drugs 611-3SBio (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- 19 Jun 2021 New trial record
Latest Information Update: 28 Jul 2022